Clinical Trial Update: Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combined PD-1 inhibition and a DNA hypomethylating agent, with or without chemotherapy, in high-risk AML or elderly patients unfit for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• DNA hypomethylating agent
• PD-1 inhibitor
• chemotherapy (optional)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit | Phase 2 | Status: UNKNOWN